Related News
Fosun to cut stake in Indian firm
Print Edition
SHANGHAI Fosun Pharmaceutical Group has agreed to cut the size of the stake it will buy in India’s Gland Pharma to 74 percent, the Chinese drugmaker said yesterday.
It said Gland Pharma’s founding family wanted to retain a higher stake in the Indian firm because of its good performance.
Fosun had previously been targetting an 86 percent stake valued at about US$1.26 billion. It said in a statement to the stock exchange that the board had approved the new plan, which would involve investment of no more than US$1.09 billion.
The deal had earlier faced some concerns in India, a source has told Reuters.
Under the new terms, Fosun Pharma said it would spend no more than US$25 million for the Indian firm’s Enoxaparin prototype sales in the US, when it gets approval there, cutting the previously proposed amount by half.
- About Us
- |
- Terms of Use
- |
-
RSS - |
- Privacy Policy
- |
- Contact Us
- |
- Shanghai Call Center: 962288
- |
- Tip-off hotline: 52920043
- 娌狪CP璇侊細娌狪CP澶05050403鍙-1
- |
- 浜掕仈缃戞柊闂讳俊鎭湇鍔¤鍙瘉锛31120180004
- |
- 缃戠粶瑙嗗惉璁稿彲璇侊細0909346
- |
- 骞挎挱鐢佃鑺傜洰鍒朵綔璁稿彲璇侊細娌瓧绗354鍙
- |
- 澧炲肩數淇′笟鍔＄粡钀ヨ鍙瘉锛氭勃B2-20120012
Copyright 漏 1999- Shanghai Daily. All rights reserved.Preferably viewed with Internet Explorer 8 or newer browsers.
